New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer

Niama Ezzaidi; Xiang Zhang; Olabisi Oluwabukola Coker; Jun Yu

doi:10.1016/j.canlet.2019.114425

New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer

Cancer Lett. 2019 Sep 10:459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.

Authors

Niama Ezzaidi¹, Xiang Zhang², Olabisi Oluwabukola Coker², Jun Yu³

Affiliations

¹ Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; MChem Chemistry and Drug Discovery, University of Sussex, UK.
² Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
³ Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. Electronic address: junyu@cuhk.edu.hk.

PMID: 31185249
DOI: 10.1016/j.canlet.2019.114425

Abstract

The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC). In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.

Keywords: Gut microbiota; Gut-liver axis; Immunity; Metabolome; NAFLD; NAFLD-HCC.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Carcinoma, Hepatocellular / microbiology*
Carcinoma, Hepatocellular / therapy
Gastrointestinal Microbiome*
Humans
Liver Neoplasms / microbiology*
Liver Neoplasms / therapy*
Non-alcoholic Fatty Liver Disease / microbiology*
Non-alcoholic Fatty Liver Disease / therapy*